Search terms: Neurological adverse events checkpoint inhibitor, checkpoint inhibitor neurology, neurological toxicities checkpoint, neurological toxicities PD-1/CTLA-4, nivolumab neurological adverse events, ipilimumab neurological adverse events, PD-1 neurological adverse events, PD-1 myasthenia gravis, PD-1 GBS, PD-1 neuropathy, checkpoint inhibitor myasthenia gravis, checkpoint inhibitor GBS, checkpoint inhibitor neuropathy, checkpoint inhibitor myositis, “encephalitis nivolumab”, and “encephalitis pembrolizumab”, “encephalitis ipilimumab”, nivolumab. Here, CTLA4 is linked to Guillain-Barre syndrome.